Search

Displaying results 1831 - 1840 of 10000 in total
  1. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    [L38814] In December 2022, atogepant received Health Canada approval for the prevention of episodic migraine in adults. … that it is the first and only oral CGRP antagonist approved for preventative use in migraine.

  2. Drug

    Idoxuridine

    go.drugbank.com/drugs/DB00249
    ApprovedWithdrawn

    An analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent.

  3. Drug

    Secukinumab

    go.drugbank.com/drugs/DB09029
    ApprovedInvestigational

    [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque

    Products: Fraizeron 150mg/ml solution for injection in pre-filled pen, Fraizeron 300mg/2ml solution for injection in pre-filled pen
  4. Drug

    Clorazepic acid

    go.drugbank.com/drugs/DB00628
    ApprovedIllicit

    In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation. … [L44798] Clorazepate and its active metabolite, nordiazepam, are present in breast milk.[A958,L44788]

    International brands: Gen-xene
  5. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    It was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.

  6. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.

  7. Drug

    Dextrothyroxine

    go.drugbank.com/drugs/DB00509
    ApprovedWithdrawn

    Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism. … Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin.

  8. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    [A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … Daridorexant reduces overactive wakefulness: in the investigational trials, daridorexant reportedly improved sleep and daytime functioning in patients with insomnia.

  9. Drug

    Chenodeoxycholic acid

    go.drugbank.com/drugs/DB06777
    ApprovedInvestigational

    Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. … It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones.

  10. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). … Linerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT).